United States: 21st Century Cures Act – Provisions Relating To Development Incentives For Certain Classes Of Drugs

On December 13, 2016, President Obama signed into law the 21st Century Cures Act (the Act), just days after it passed in the U.S. House of Representatives and Senate.  With an overarching goal of advancing biomedical innovation, the Act makes numerous changes to laws that govern Food and Drug Administration (FDA) programs, clinical research regulations, and Medicare coverage and reimbursement rules.

To see Ropes & Gray's analysis of key provisions of the Act, please click on the hyperlinks below:

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter